3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
102
fludarabine phosphate
94
Mycophenolic Acid
81
Tacrolimus
70
Whole-Body Irradiation
65
Peripheral Blood Stem Cell Transplantation
65
fludarabine
49
Busulfan
49
Cyclosporine
48
Antilymphocyte Serum
44
Melphalan
39
Filgrastim
37
Methotrexate
32
Radiotherapy
25
Granulocyte Colony-Stimulating Factor
22
Cord Blood Stem Cell Transplantation
20
Sirolimus
19
Rituximab
19
thymoglobulin
18
Stem Cell Transplantation
18
Methylprednisolone
16
Alemtuzumab
16
Thiotepa
13
sargramostim
11
Cytarabine
11
Cyclosporins
11
Clofarabine
11
Therapeutics
10
Flow Cytometry
10
Etoposide
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
angiotensin I (1-7)
×
Myeloid
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled